VFIC
SPRY icon

Valley Forge Investment Consultants’s ARS Pharmaceuticals SPRY Stock Holding History

Valley Forge Investment Consultants’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$668K Hold
83,225
– – 0.2% 39
2025
Q4 		$970K Hold
83,225
– – 0.28% 31
2025
Q3 		$836K Hold
83,225
– – 0.24% 35
2025
Q2 		$1.45M Hold
83,225
– – 0.47% 23
2025
Q1 		$1.05M Hold
83,225
– – 0.37% 26
2024
Q4 		$878K Hold
83,225
– – 0.3% 34
2024
Q3 		$1.21M Buy
+83,225
New +$990K 0.42% 24

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Valley Forge Investment Consultants's SPRY Position: Q1 2026 in Review

Valley Forge Investment Consultants held its ARS Pharmaceuticals (SPRY) position steady in Q1 2026 at 83,225 shares worth $668K. The position accounts for 0.2% of the portfolio, ranked #39.

Valley Forge Investment Consultants first reported a position in SPRY in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.45M in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Valley Forge Investment Consultants held 83,225 shares of ARS Pharmaceuticals worth $668K as of Q1 2026.
  • Valley Forge Investment Consultants left its ARS Pharmaceuticals share count unchanged in Q1 2026.
  • ARS Pharmaceuticals made up 0.2% of Valley Forge Investment Consultants's portfolio in Q1 2026, its #39 holding.
  • Valley Forge Investment Consultants first reported a position in ARS Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Valley Forge Investment Consultants's ARS Pharmaceuticals position peaked at $1.45M in Q2 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Valley Forge Investment Consultants's 13F filing for Q1 2026, filed 21 Apr 2026.